Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease.
J Pharmacokinet Pharmacodyn. 2021 Feb;48(1):21-38. doi: 10.1007/s10928-020-09716-x. Epub 2020 Sep 14.
J Pharmacokinet Pharmacodyn. 2021.
PMID: 32929612
Free PMC article.
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model.
Snelder N, Hoefman S, Garcia-Hernandez A, Onkels H, Larsson TE, Bergmann KR.
Snelder N, et al. Among authors: onkels h.
J Pharmacokinet Pharmacodyn. 2021 Feb;48(1):39-53. doi: 10.1007/s10928-020-09717-w. Epub 2020 Sep 15.
J Pharmacokinet Pharmacodyn. 2021.
PMID: 32930923
Free PMC article.
Item in Clipboard
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H.
Kadokura T, et al. Among authors: onkels h.
Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):1-9. doi: 10.1007/s13318-013-0141-1. Epub 2013 Jun 11.
Eur J Drug Metab Pharmacokinet. 2014.
PMID: 23754514
Clinical Trial.
Item in Clipboard
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C, Onkels H.
Groenendaal D, et al. Among authors: onkels h.
Br J Clin Pharmacol. 2013 Feb;75(2):440-9. doi: 10.1111/j.1365-2125.2012.04346.x.
Br J Clin Pharmacol. 2013.
PMID: 22642721
Free PMC article.
Item in Clipboard
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H.
Kadokura T, et al. Among authors: onkels h.
Biopharm Drug Dispos. 2013 Nov;34(8):431-41. doi: 10.1002/bdd.1858. Epub 2013 Sep 20.
Biopharm Drug Dispos. 2013.
PMID: 23929659
Clinical Trial.
Item in Clipboard
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C, Onkels H.
Groenendaal D, et al. Among authors: onkels h.
Clin Pharmacol Drug Dev. 2014 May;3(3):194-201. doi: 10.1002/cpdd.93. Epub 2014 Mar 3.
Clin Pharmacol Drug Dev. 2014.
PMID: 27128609
Clinical Trial.
Item in Clipboard
Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Hashimoto T, Suzuki K, Kihara Y, Iwatsubo T, Miyashita A, Heeringa M, Onkels H, Groenendaal D, Verheggen F, van Marle S, Usui T.
Hashimoto T, et al. Among authors: onkels h.
Xenobiotica. 2013 Jun;43(6):534-47. doi: 10.3109/00498254.2012.738045. Epub 2012 Nov 20.
Xenobiotica. 2013.
PMID: 23167531
Clinical Trial.
Item in Clipboard
Cite
Cite